Drug Repurposing of Loratadine as a DNMT1 Inhibitor: Comparative Evaluation with Cisplatin in Patient-Derived Oral Squamous Cell Carcinoma Cells. (2024). Precision Medicine Communications, 4(2), 125-137. https://doi.org/10.55627/pmc.004.02.1083